1. Home
  2. MLYS vs ACIC Comparison

MLYS vs ACIC Comparison

Compare MLYS & ACIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • ACIC
  • Stock Information
  • Founded
  • MLYS 2019
  • ACIC 1999
  • Country
  • MLYS United States
  • ACIC United States
  • Employees
  • MLYS N/A
  • ACIC N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • ACIC Property-Casualty Insurers
  • Sector
  • MLYS Health Care
  • ACIC Finance
  • Exchange
  • MLYS Nasdaq
  • ACIC Nasdaq
  • Market Cap
  • MLYS 890.6M
  • ACIC 556.0M
  • IPO Year
  • MLYS 2023
  • ACIC N/A
  • Fundamental
  • Price
  • MLYS $37.29
  • ACIC $11.13
  • Analyst Decision
  • MLYS Strong Buy
  • ACIC Buy
  • Analyst Count
  • MLYS 6
  • ACIC 1
  • Target Price
  • MLYS $42.60
  • ACIC $16.00
  • AVG Volume (30 Days)
  • MLYS 2.6M
  • ACIC 169.5K
  • Earning Date
  • MLYS 11-10-2025
  • ACIC 11-05-2025
  • Dividend Yield
  • MLYS N/A
  • ACIC 4.45%
  • EPS Growth
  • MLYS N/A
  • ACIC 14.01
  • EPS
  • MLYS N/A
  • ACIC 1.63
  • Revenue
  • MLYS N/A
  • ACIC $320,072,000.00
  • Revenue This Year
  • MLYS N/A
  • ACIC $4.91
  • Revenue Next Year
  • MLYS N/A
  • ACIC $4.16
  • P/E Ratio
  • MLYS N/A
  • ACIC $6.88
  • Revenue Growth
  • MLYS N/A
  • ACIC 33.90
  • 52 Week Low
  • MLYS $8.24
  • ACIC $8.82
  • 52 Week High
  • MLYS $39.20
  • ACIC $15.08
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 82.81
  • ACIC 53.71
  • Support Level
  • MLYS $34.59
  • ACIC $10.71
  • Resistance Level
  • MLYS $39.20
  • ACIC $11.17
  • Average True Range (ATR)
  • MLYS 2.83
  • ACIC 0.35
  • MACD
  • MLYS 0.73
  • ACIC -0.02
  • Stochastic Oscillator
  • MLYS 92.13
  • ACIC 43.90

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About ACIC American Coastal Insurance Corporation

American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.

Share on Social Networks: